The myosin heavy chain 10 (MYH10) gene is located on human chromosome 17, which encodes the non-muscle myosin II B (NM IIB). Therefore, it is critical to investigate the mechanisms driving the initiation, progression, and cisplatin resistance of SOC, which would help to identify novel effective therapeutic approaches and improve the prognosis of SOC patients. The poor prognosis of SOC is due to its high invasive capacity and cisplatin resistance of SOC cells.

With the rapid development of new therapeutic approaches, the prognosis of SOC has improved, but its mortality remained very high. Among epithelial ovarian cancers, serous ovarian cancer (SOC) is the most important subtype. Epithelial ovarian cancer is the most common type of OC. Globally, there are 239 000 new cases and 152 000 deaths of OC every year. Ovarian cancer (OC) is the leading cause of cancer-related mortality among female reproductive malignant cancers in China. These findings uncover a key role of the MYH10-MYH9-snail axis in SOC carcinogenesis, progression, and cisplatin resistance, and provide potential novel therapeutic targets for SOC intervention. MYH10+/MYH9+ co-expression is an independent prognostic factor for predicting SOC patient survival. And the expression of MYH10 is positively correlated with MYH9 expression. In clinical samples, MYH10 expression is significantly elevated in SOC samples compared to the paratumor samples. Further studies confirm that the MYH10 protein functional domain combines with non-muscle myosin heavy chain IIA (MYH9) to recruit the deubiquitinating enzyme Ubiquitin-specific proteases 45 and deubiquitinates snail to inhibit snail degradation, eventually promoting tumorigenesis, progression, and cisplatin resistance in SOC. The results show that the knockdown of MYH10 suppressed SOC cell proliferation, migration, invasion, metastasis, and cisplatin resistance both in vivo and in vitro. The mechanism of MYH10 is demonstrated by co-immunoprecipitation, GST pull-down, confocal laser assays, and so on.

In the present study, the expression and function of non-muscle myosin heavy chain IIB (MYH10) in SOC are identified by immunohistochemistry, in vitro, and in vivo studies, respectively. The poor prognosis of serous ovarian cancer (SOC) is due to its high invasive capacity and cisplatin resistance of SOC cells, whereas the molecular mechanisms remain poorly understood.

Calculate ic50 in prism